Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: 2-5A antisense compounds - IFN

Drug Profile

Research programme: 2-5A antisense compounds - IFN

Alternative Names: MP 351; NIH 351; spA4-anti-hTr

Latest Information Update: 23 Apr 2003

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); The Cleveland Clinic Foundation
  • Developer IFN
  • Class Antivirals
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; RNA inhibitors; Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Respiratory syncytial virus infections
  • Discontinued Acne; Alopecia

Most Recent Events

  • 05 May 2001 Gemini has sold all of its assets relating to 2-5A antisense technology to IFN
  • 31 Dec 2000 Discontinued - Preclinical for Acne in USA (unspecified route)
  • 31 Dec 2000 Discontinued - Preclinical for Alopecia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top